IMV Inc. Announces Second Quarter 2022 Financial and Operati

11.08.2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its ...

Related Keywords

New York , United States , Australia , New Zealand , Paris , France General , France , Toronto , Ontario , Canada , America , American , Matthewj Matasar , Jeremyr Graff , Oliver Dorigo , Department Of Obstetrics , Linkedin , Twitter , American Association Of Cancer Research , Horizon Technology Finance Corporation Nasdaq , Nasdaq , Division Gynecologic Oncology , Company Is Exploring The Optimal Development Pathway , European Society For Medical Oncology , Stanford University , Clinical Programs , North America , Section Head , Aggressiveb Cell Lymphoma , Memorial Sloan Kettering Cancer Center , European Society , Medical Oncology , Platinum Resistant Ovarian , Associate Professor , Optimal Development Pathway , Scientific Officer , American Association , Cancer Research , Existing Long Term Debt , Horizon Technology Finance Corporation , Second Quarter , Diffuse Largeb Cell Lymphoma , Comprehensive Loss , Gimv ,